Integer (NYSE:ITGR) Stock Price Expected to Rise, Benchmark Analyst Says

Integer (NYSE:ITGR) had its price objective increased by Benchmark from $140.00 to $150.00 in a research report report published on Friday,Benzinga reports. Benchmark currently has a buy rating on the medical equipment provider’s stock.

A number of other research analysts have also recently commented on the stock. Wells Fargo & Company reiterated an “overweight” rating and set a $160.00 price target on shares of Integer in a research report on Tuesday, December 3rd. KeyCorp raised their target price on shares of Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Oppenheimer cut shares of Integer from an “outperform” rating to a “market perform” rating in a report on Friday. Truist Financial raised their target price on shares of Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, Citigroup raised their target price on shares of Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a report on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Integer presently has a consensus rating of “Moderate Buy” and an average price target of $147.67.

Integer Stock Down 3.9 %

Shares of NYSE ITGR opened at $129.96 on Friday. Integer has a one year low of $98.63 and a one year high of $146.36. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09. The firm’s 50 day simple moving average is $137.74 and its two-hundred day simple moving average is $132.58. The stock has a market capitalization of $4.37 billion, a P/E ratio of 38.68, a PEG ratio of 1.72 and a beta of 1.13.

Integer (NYSE:ITGR) last issued its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). Integer had a net margin of 6.92% and a return on equity of 11.65%. The business had revenue of $449.50 million for the quarter, compared to the consensus estimate of $446.28 million. As a group, analysts expect that Integer will post 6.01 EPS for the current fiscal year.

Institutional Trading of Integer

Several large investors have recently added to or reduced their stakes in ITGR. Blue Trust Inc. lifted its position in Integer by 4.4% during the fourth quarter. Blue Trust Inc. now owns 1,689 shares of the medical equipment provider’s stock valued at $220,000 after buying an additional 71 shares during the period. Arizona State Retirement System raised its position in Integer by 0.9% in the 4th quarter. Arizona State Retirement System now owns 9,732 shares of the medical equipment provider’s stock worth $1,290,000 after buying an additional 84 shares during the last quarter. HighTower Advisors LLC grew its stake in shares of Integer by 0.8% during the 3rd quarter. HighTower Advisors LLC now owns 12,041 shares of the medical equipment provider’s stock valued at $1,579,000 after purchasing an additional 90 shares during the period. HighPoint Advisor Group LLC grew its stake in shares of Integer by 6.4% during the 4th quarter. HighPoint Advisor Group LLC now owns 1,684 shares of the medical equipment provider’s stock valued at $234,000 after purchasing an additional 101 shares during the period. Finally, Norden Group LLC grew its stake in shares of Integer by 7.0% during the 4th quarter. Norden Group LLC now owns 1,668 shares of the medical equipment provider’s stock valued at $221,000 after purchasing an additional 109 shares during the period. Institutional investors own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.